aTyr Pharma Inc
NASDAQ:ATYR

Watchlist Manager
aTyr Pharma Inc Logo
aTyr Pharma Inc
NASDAQ:ATYR
Watchlist
Price: 3.97 USD -0.5% Market Closed
Market Cap: 333.2m USD
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one ATYR stock under the Base Case scenario is hidden USD. Compared to the current market price of 3.97 USD, aTyr Pharma Inc is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ATYR Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

1 418.1
P/S
P/S
Price to Sales
1 418.1
vs History
0
vs Industry
Median 3Y
17.5
Median 5Y
38.2
Industry
7.3
Forward
1 766
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-4
Median 5Y
-5.9
Industry
21.6
Forward
-4.3
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-4.7
Median 5Y
-6.3
Industry
19.8
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-4.4
Median 5Y
-6.2
Industry
24.9
More Details
5.1
P/B
P/B
Price to Book Value
5.1
vs History
39
vs Industry
Median 3Y
2.4
Median 5Y
3.9
Industry
2.4
More Details
1 141.6
EV/S
EV/S
Enterprise Value to Sales
1 141.6
vs History
0
vs Industry
Median 3Y
7.5
Median 5Y
33.3
Industry
7.4
Forward
1 421.7
More Details
N/A
EV/GP
EV/GP
Enterprise Value to Gross Profit
N/A
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
9.3
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-2.3
Median 5Y
-4
Industry
3.9
Forward
-4
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-2.3
Median 5Y
-3.9
Industry
3.7
Forward
-3.7
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-2.6
Median 5Y
-4.1
Industry
4.9
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-2.5
Median 5Y
-4.1
Industry
3.2
More Details
12.4
EV/IC
EV/IC
Enterprise Value to IC
12.4
vs History
52
vs Industry
Median 3Y
4.2
Median 5Y
26.1
Industry
4.3
More Details

Multiples Across Competitors

ATYR Competitors Multiples
aTyr Pharma Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
aTyr Pharma Inc
NASDAQ:ATYR
333.2m USD 1 418.1 -5.2 -4 -3.9
FR
Pharnext SCA
OTC:PNEXF
6T USD 36 551 680.7 -173 724.7 -210 957.2 -208 549.9
US
Abbvie Inc
NYSE:ABBV
373.8B USD 6.6 88.2 17.2 26
US
Amgen Inc
NASDAQ:AMGN
168.4B USD 5 41.2 16.6 29.3
US
Gilead Sciences Inc
NASDAQ:GILD
138.9B USD 4.8 289.3 11.3 14.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
129.7B USD 11.8 -242.2 26.5 27.8
US
Epizyme Inc
F:EPE
94.1B EUR 1 927.4 -491.8 -535.6 -521.3
AU
CSL Ltd
ASX:CSL
121.1B AUD 5 27.9 17.2 21.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
73.1B USD 5.1 16.6 10.9 12.2
US
Seagen Inc
F:SGT
39.3B EUR 18.6 -56.9 -61.2 -55.3
NL
argenx SE
XBRU:ARGX
32.9B EUR 16.3 42.9 316.7 -2 333.5
P/S Multiple
Revenue Growth P/S to Growth
US
aTyr Pharma Inc
NASDAQ:ATYR
Average P/S: 3 323 190.9
1 418.1
358%
4
FR
Pharnext SCA
OTC:PNEXF
36 551 680.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
8%
0.8
US
Amgen Inc
NASDAQ:AMGN
5
4%
1.3
US
Gilead Sciences Inc
NASDAQ:GILD
4.8
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.8
10%
1.2
US
E
Epizyme Inc
F:EPE
1 927.4
N/A N/A
AU
CSL Ltd
ASX:CSL
5
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.1
7%
0.7
US
S
Seagen Inc
F:SGT
18.6
30%
0.6
NL
argenx SE
XBRU:ARGX
16.3
37%
0.4
P/E Multiple
Earnings Growth PEG
US
aTyr Pharma Inc
NASDAQ:ATYR
Average P/E: 84.3
Negative Multiple: -5.2 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -173 724.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
88.2
88%
1
US
Amgen Inc
NASDAQ:AMGN
41.2
44%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
289.3
185%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -242.2 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -491.8 N/A N/A
AU
CSL Ltd
ASX:CSL
27.9
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.6
11%
1.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -56.9 N/A N/A
NL
argenx SE
XBRU:ARGX
42.9
19%
2.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
aTyr Pharma Inc
NASDAQ:ATYR
Average EV/EBITDA: 59.5
Negative Multiple: -4 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -210 957.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
17.2
13%
1.3
US
Amgen Inc
NASDAQ:AMGN
16.6
14%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
11.3
6%
1.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.5
16%
1.7
US
E
Epizyme Inc
F:EPE
Negative Multiple: -535.6 N/A N/A
AU
CSL Ltd
ASX:CSL
17.2
12%
1.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.9
17%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.2 N/A N/A
NL
argenx SE
XBRU:ARGX
316.7
168%
1.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
aTyr Pharma Inc
NASDAQ:ATYR
Average EV/EBIT: 21.8
Negative Multiple: -3.9 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -208 549.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
26
29%
0.9
US
Amgen Inc
NASDAQ:AMGN
29.3
31%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
14.2
10%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.8
15%
1.9
US
E
Epizyme Inc
F:EPE
Negative Multiple: -521.3 N/A N/A
AU
CSL Ltd
ASX:CSL
21.5
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
12.2
17%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.3 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 333.5 N/A N/A

See Also

Summary
ATYR intrinsic value, competitors valuation, and company profile.
DCF Valuation
ATYR stock valuation using Discount Cash Flow valuation method.
Relative Valuation
ATYR stock valuation using valuation multiples.
Wall Street Estimates
ATYR price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
ATYR stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 238,600+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.